Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

EpiCept and Immune Pharmaceuticals merge

Executive Summary

EpiCept Corp. (developing therapies for pain and cancer) will issue shares of its own common stock to acquire all of the outstanding shares of privately owned Immune Pharmaceuticals Ltd. (antibodies for inflammatory diseases and oncology). The value of the deal has not been disclosed, but is structured as a reverse merger, with EpiCept shareholders owning 22.5% of the combined entity--Immune Pharmaceuticals Inc.--and Immune Pharmaceuticals Ltd. shareholders owning 77.5%.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Intra-Biotech Deal
    • Payment Includes Stock
    • Reverse Acquisition

Related Companies